Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep;27(9):1751-1753.
doi: 10.1111/ene.14368.

SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome

A M Lascano  1 , J-B Epiney  2 , M Coen  3 , J Serratrice  3 , R Bernard-Valnet  2 , P H Lalive  1 , T Kuntzer  2 , A Hübers  1
Affiliations
Case Reports

SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome

A M Lascano et al. Eur J Neurol. 2020 Sep.

Abstract

Background and purpose: The spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system.

Methods: From March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barré syndrome (GBS) following SARS-CoV-2.

Results: These cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance.

Conclusions: We report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage.

Keywords: COVID-19; electrodiagnostic testing; immune-mediated disorder; immunoglobulin therapy; infection; polyradiculoneuropathy.

PubMed Disclaimer

Conflict of interest statement

Dr Kuntzer reports grants from International CSL‐Behring, outside the submitted work. Dr Lalive received honoraria for speaking for Biogen‐Idec, CSL Behring, Merck Serono, Novartis, Sanofi‐Aventis, Teva, Roche, consulting fees from Biogen‐Idec, Geneuro, Genzyme, Merck Serono, Novartis, Sanofi‐Aventis, Teva, and research grants from Biogen‐Idec, Merck Serono, Novartis. Drs Lascano, Epiney, Coen, Bernard‐Valnet, Serratrice and Hübers have nothing to disclose.

References

    1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395: 470–473. - PMC - PubMed
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061. - PMC - PubMed
    1. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS‐CoV‐2 infection. N Engl J Med 2020; 382: 2268–2270. - PMC - PubMed
    1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurology 2020; 77: 683–690. - PMC - PubMed
    1. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain‐Barre syndrome associated with SARS‐CoV‐2 infection: causality or coincidence? Lancet Neurol 2020; 19: 383–384. - PMC - PubMed

Publication types

Substances